SCHEMBL5548019

SCHEMBL5548019

O=COCCc1nnnn1-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 6/20 0.53
PKM P14618 2/20 0.52
HTT P42858 1/20 0.52
NLRP3 Q96P20 1/20 0.52
ALDH1A1 P00352 12/20 0.49
KMT2A Q03164 3/20 0.49
TSHR P16473 3/20 0.49
MEN1 O00255 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
LMNA P02545 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.45
THRB P10828 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.42
HPGD P15428 1/20 0.42
MAPT P10636 2/20 0.41
NPC1 O15118 1/20 0.41
NFKB1 P19838 1/20 0.41
RAB9A P51151 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546087 0.86 HSD11B1 (0.50) HSD11B1PKMHTTNLRP3ALDH1A1
SCHEMBL5543439 0.86 ALDH1A1 (0.48) HSD11B1PKMHTTNLRP3ALDH1A1
SCHEMBL5537177 0.86 ALDH1A1 (0.49) HSD11B1PKMHTTNLRP3ALDH1A1
SCHEMBL5543973 0.85 POLB (0.45) HSD11B1PKMHTTNLRP3ALDH1A1
SCHEMBL5536571 0.84 HSD11B1 (0.44) HSD11B1PKMHTTNLRP3ALDH1A1
SCHEMBL5537091 0.84 ALDH1A1 (0.42) HSD11B1PKMHTTNLRP3ALDH1A1
SCHEMBL5539749 0.82 KCNN4 (0.41) HSD11B1PKMHTTNLRP3ALDH1A1
SCHEMBL4675275 0.81 HSD11B1 (0.64) HSD11B1PKMHTTNLRP3ALDH1A1
SCHEMBL5548018 0.79 HSD11B1 (0.53) HSD11B1PKMHTTNLRP3ALDH1A1
SCHEMBL2968355 0.78 HSD11B1 (0.61) HSD11B1PKMHTTNLRP3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HSD11B1 256/4885PKM 4291/4885HTT 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.